Loading the session
Loading the session
Loading instrument
$15.30
+0.00%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:40 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −18.0% (SPY −1.6%). 3 months: −42.3% (SPY −0.4%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: APMD, SPY · as of 4 Nov 2026
The 4 Nov 2026 close of $15.30 was 31.2% below its 50-day average ($22.23).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
1.8M shares were sold short at the 15 Oct 2026 settlement; covering them would take 3.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
October 6, 2026
−14.25%September 23, 2026
−11.84%August 31, 2026
−11.65%